168.1500 0.11 (0.07%)
NSE Apr 02, 2026 15:31 PM
Volume: 550.7K
 

Dynamic Levels
Marksans R&D; capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development and conducting stability studies. The company has a team of over 50 experienced scientists specializing in formulation development and analytical development. The conpany has possessed end-to-end capabilities from Lab scale development to Pilot scale up and from commercializing the product for large...
Number of FII/FPI investors decreased from 146 to 137 in Dec 2025 qtr
More from Marksans Pharma Ltd.
Recommended